Medicine by the Numbers
A Collaboration of TheNNT.com and AFP
Antibiotic Prophylaxis in Patients with COPD
Am Fam Physician. 2019 Jun 1;99(11):online.
Details for This Review
Study Population: Patients older than 40 years with spirometry-proven diagnosis of moderate to severe chronic obstructive pulmonary disease (COPD)
Efficacy End Points: COPD exacerbations, frequency of exacerbations, time to first exacerbation, and health-related quality of life as measured by the St. George's Respiratory Questionnaire or the Chronic Respiratory Diseases Questionnaire
Harm End Points: Drug resistance as measured by microbial sensitivity, adverse drug effects, hospitalization, and all-cause mortality
Narrative: COPD is defined as persistent respiratory symptoms and airflow obstruction caused by alveolar and airway dysfunction resulting from exposure to noxious particles and gases.1 It is common throughout the world and is the third leading cause of death in the United States.2 Morbidity from COPD is costly, reducing the capacity for work3 and increasing the number of emergency department visits and hospitalizations.4 It can profoundly reduce quality of life, causing social isolation and depression.5,6 Viral infections account for most exacerbations, but bacterial colonization increases with the severity of COPD, and bacterial infections are more common in acute exacerbations.7
In theory, antibiotics provide their benefit by decreasing bacterial growth, potentially limiting the inflammatory effects of the bacteria.8,9 Prophylactic antibiotics were routinely administered for cases of chronic bronchitis 30 years ago, but this practice declined amid concern for antibiotic resistance without evidence of efficacy.
The Cochrane group identified 14 randomized controlled trials of antibiotics compared with placebo, with end points of prevention of COPD exacerbations or improved quality of life. The studies were published or presented between 2001 and 2017 and included a total of 3,932 participants. Nine trials studied continuous macrolide antibiotic treatment (1,925 participants); two examined antibiotics administered three times weekly (176 participants); two studied pulsed antibiotics given three days per month or five days every eight weeks (1,732 participants), and one trial compared three arms: continuous doxycycline vs. azithromycin (Zithromax) administered three times weekly vs. moxifloxacin (Avelox) for five days every month (99 participants). The heterogeneity of the studies was moderate.
Copyright © 2019 MD Aware, LLC (theNNT.com). Used with permission.
Referencesshow all references
1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed January 25, 2019....
2. National Center for Health Statistics. Health, United States 2015: with Special Feature on Racial and Ethnic Health Disparities. Hyattsville, Md.: U.S. Department of Health and Human Services; 2016.
3. Wheaton AG, Cunningham TJ, Ford ES, Croft JB; Centers for Disease Control and Prevention (CDC). Employment and activity limitations among adults with chronic obstructive pulmonary disease—United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(11):289–295.
4. Wheaton AG, Ford ES, Cunningham TJ, Croft JB. Chronic obstructive pulmonary disease, hospital visits, and comorbidities: National Survey of Residential Care Facilities, 2010. J Aging Health. 2015;27:480–499.
5. Liu Y, Croft JB, Anderson LA, Wheaton AG, Presley-Cantrell LR, Ford ES. The association of chronic obstructive pulmonary disease, disability, engagement in social activities, and mortality among US adults aged 70 years or older, 1994–2006. Int J Chron Obstruct Pulmon Dis. 2014;9:75–83.
6. Cunningham TJ, Ford ES, Rolle IV, Wheaton AG, Croft JB. Association of self-reported cigarette smoking with chronic obstructive pulmonary disease and co-morbid chronic conditions in the United States. COPD. 2015;12(3):276–286.
7. Woodhead M, Blasi F, Ewig S, et al.; Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect. 2011;17(suppl 6):E1–E59.
8. Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respir Med. 2013;107(1):10–22.
9. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(3):331–350.
10. Hu Y, Coates A. Nonmultiplying bacteria are profoundly tolerant to antibiotics. In: Coates AR, ed. Antibiotic Resistance. Handbook of Experimental Pharmacology. Vol. 211. New York, NY: Springer; 2012:99–120.
This series is coordinated by Dean A. Seehusen, MD, MPH, AFP Assistant Medical Editor, and Daniel Runde, MD, from the NNT Group.
A collection of Medicine by the Numbers published in AFP is available at https://www.aafp.org/afp/mbtn.
Copyright © 2019 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions